Search
Now showing items 31-34 of 34
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
(NATURE PUBLISHING GROUP, 2018-03-20)
This corrects the article DOI: 10.1038/bjc.2017.429.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
(ELSEVIER SCIENCE INC, 2016-08-01)
BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a ...
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.
(WILEY, 2016-06-01)
BACKGROUND: A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and ...
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
(ELSEVIER, 2019-12-01)
BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ...